In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG)
Y. M. Van Der Geld
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorM. G. Huitema
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorC. F. M. Franssen
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorR. Van Der Zee
Institute of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
Search for more papers by this authorP. C. Limburg
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorC. G. M. Kallenberg
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorY. M. Van Der Geld
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorM. G. Huitema
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorC. F. M. Franssen
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorR. Van Der Zee
Institute of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
Search for more papers by this authorP. C. Limburg
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorC. G. M. Kallenberg
Department of Internal Medicine, University Hospital Groningen, Groningen, and
Search for more papers by this authorAbstract
T cell-mediated immunity is thought to play an important role in the pathogenesis of WG. In previous studies a minority of WG patients as well as some healthy controls showed in vitro proliferation of their peripheral blood mononuclear cells (PBMC) to PR3, the main autoantigen in WG. The relevant peptides responsible for this in vitro proliferation have not been identified. In order to define immunogenic peptides, PBMC of 13 WG patients in remission and 10 healthy controls were tested for proliferation to linear peptides of PR3 and to whole PR3. Fifty overlapping peptides spanning the whole PR3 sequence were synthesized. Peptides were tested in pools of five peptides and as single peptide. PBMC of two WG patients and one healthy control proliferated to whole PR3 and to peptide pools. In addition, 10 WG patients and eight healthy controls that did not proliferate to whole PR3 did proliferate to pools of PR3 peptides. Although more WG patients tended to react to particular peptide pools, no significant difference was seen between lymphocyte proliferation to PR3 peptides of WG patients and that of healthy controls. The pools of peptides recognized were mainly located at the N- and C-terminus of PR3. No correlation was observed between HLA type and proliferation on particular peptide pools. No proliferation of PBMC was observed to single peptides. In conclusion, T cells of WG patients proliferate in vitro more frequently to PR3 peptides than to the whole PR3 protein. Peptides derived from the signal sequence, the propeptide or peptides located at the C-terminus of PR3 induce highest levels of proliferation. No specific PR3 sequence could be identified that was preferentially recognized by PBMC of WG patients compared with controls.
References
- 1 Fauci AS, Haynes BF, Katz P & Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.
- 2 Van Der Woude FJ, Rasmussen N & Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425–9.
- 3 Goldschmeding R, Van Der Schoot CE, Ten Bokkel Huinink D, Hack CE, Van Den Ende ME, Von Kallenberg CGM & Dem Borne AEGKR. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577–87.
- 4 Niles JL, McCluskey RT, Ahmad MF & Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989; 74: 1888–93.
- 5 Lüdemann J, Utecht B & Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med 1990; 171: 357–62.
- 6 Cohen Tervaert JW, Van Der Woude FJ & Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149: 2461–5.
- 7 Kallenberg CGM, Brouwer E, Weening JJ & Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1–15.
- 8 Gephardt GN, Ahmad M & Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med 1983; 74: 700–4.
- 9 Rastaldi MP, Ferrario F, Tunesi S, Yang L & D'amico G. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-1 alpha expression in 15 cases of antineutrophil cytoplasmic autoantibody-associated renal vasculitis. Am J Kidney Dis 1996; 27: 48–57.
- 10 Brouwer E, Cohen Tervaert JW, Weening JJ & Kallenberg CGM. Immunohistopathology of renal biopsies in Wegener's granulomatosis (WG): clues to its pathogenesis? Kidney Int 1991; 39 (Abstr.): 1055–6.
- 11 Schlesier M, Kaspar T, Gutfleisch J, Wolff Vorbeck G & Peter HH. Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995; 14: 213–9.
- 12 Popa ER, Stegeman CA, Bos NA, Kallenberg CGM & Cohen Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103: 885–94.
- 13 Schmitt WH, Heesen C, Csernok E, Rautmann A & Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35: 1088–96.
- 14 Stegeman CA, Cohen Tervaert JW, Huitema MG & Kallenberg CGM. Serum markers of T-cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993; 91: 415–20.
- 15 Wang G, Hansen H, Tatsis E, Csernok E, Lemke H & Gross WL. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517–23.
- 16 D'cruz D, Direskeneli H, Khamashta M & Hughes GR. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity. J Rheumatol 1999; 26: 103–9.
- 17 Brouwer E, Cohen Tervaert JW, Horst G, Huitema MG, Van Der Giessen M, Limburg PC & Kallenberg CGM. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991; 83: 379–86.
- 18 Hagen EC, De Keizer RJ, Andrassy K, Van Boven WP, Bruijn JA, Van Es LA & Van Der Woude FJ. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995; 43: 351–9.
- 19 Haubitz M, Koch KM & Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13: 2074–6.
- 20 Mathieson PW, Lockwood CM & Oliveira DB. T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Immunol Immunopathol 1992; 63: 135–41.
- 21 Rasmussen N & Petersen J. Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J Autoimmun 1993; 6: 227–36.
- 22 Brouwer E, Stegeman CA, Huitema MG, Limburg PC & Kallenberg CGM. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1994; 98: 448–53.
- 23 Ballieux BE, Van Der Burg SH, Hagen EC, Van Der Woude FJ, Melief CJ & Daha MR. Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 1995; 100: 186–93.
- 24 Griffith ME, Coulthart A & Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103: 253–8.
- 25 King WJ, Brooks CJ, Holder R, Hughes P, Adu D & Savage COS. T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998; 112: 539–46.
- 26 Mayet WJ, Marker-Hermann E, Schlaak J & Meyer zum Buschenfelde KM. Irregular cytokine pattern of CD4+ T lymphocytes in response to Staphylococcus aureus in patients with Wegener's granulomatosis. Scand J Immunol 1999; 49: 585–94.
- 27 Leavitt RY, Fauci AS & Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101–7.
- 28 Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl 1989; 6: 12–13.
- 29 Van Der Giessen M, Huitema MG, Cohen Tervaert JW & Kallenberg CGM. A technical note on the routinely performed ANCA detection. APMIS 1989; 97: 37.
- 30 Cohen Tervaert JW, Goldschmeding R & Elema JD et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37: 799–806.
- 31 Olerup O & Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225–35.
- 32 Van der Geld YM, Oost Kort WW, Limburg PC, Specks U & Kallenberg CGM. Recombinant proteinase 3 (PR3) produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods 2000; 244: 117–31.
- 33 Boomsma MM, Stegeman CA, Van Der Leij MJ, Oost-kort WW, Hermans J, Kallenberg CGM, Limburg PC & Cohen Tervaert JW. Prediction of relapses in Wegener's granulomatosis by measurement of anti neutrophil cytoplasmic antibody levels; a prospective study. Arthritis Rheum 2000; 43: 2025–33.
- 34 Labbaye C, Musette P & Cayre YE. Wegener autoantigen and myeloblastin are encoded by a single mRNA. Proc Natl Acad Sci USA 1991; 88: 9253–6.
- 35 Van Der Zee R, Anderton SM, Buskens CAF, Alonso de Velasco E & Van Eden W. Heat shock protein T cell epitopes as immunogenic carriers in subunit vaccines. In: HLS Maya, ed. Peptides 1994, Proceedings of the Twenty-Third European Peptide Symposium, ESCOM Leiden, 1994: 841–2.
- 36 Prelli F, Pras M & Frangione B. The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis. J Biol Chem 1985; 260: 12895–8.
- 37 Adorini L, Moreno J, Momburg F, Hammerling GJ, Guery JC, Valli A & Fuchs S. Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex class II-restricted T cells. J Exp Med 1991; 174: 945–8.
- 38 Sinigaglia F & Hammer J. Defining rules for the peptide–MHC class II interaction. Curr Opin Immunol 1994; 6: 52–56.
- 39 Maffei A & Harris PE. Peptides bound to major histocompatibility complex molecules. Peptides 1998; 19: 179–98.
- 40 Liblau R, Tournier Lasserve E, Maciazek J, Dumas G, Siffert O, Hashim G & Bach MA. T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects. Eur J Immunol 1991; 21: 1391–5.
- 41 Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL & Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94: 2125–9.
- 42 Naquet P, Ellis J, Tibensky D, Kenshole A, Singh B, Hodges R & Delovitch TL. T cell autoreactivity to insulin in diabetic and related non-diabetic individuals. J Immunol 1988; 140: 2569–78.
- 43 Harcourt GC, Sommer N, Rothbard J, Willcox HN & Newsom Davis J. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J Clin Invest 1988; 82: 1295–300.
- 44 Campanelli D, Melchior M, Fu Y, Nakata M, Shuman H, Nathan C & Gabay JE. Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils. J Exp Med 1990; 172: 1709–15.
- 45 Rao NV, Rao GV, Marshall BC & Hoidal JR. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. J Biol Chem 1996; 271: 2972–8.
- 46 Sinha S, Watorek W, Karr S, Giles J, Bode W & Travis J. Primary structure of human neutrophil elastase. Proc Natl Acad Sci USA 1987; 84: 2228–32.
- 47 Van der Geld YM, Simpelaar A, Van Der Zee R, Cohen Tervaert JW, Stegeman CA, Limburg PC & Kallenberg CGM. Epitope mapping of ANCA positive sera of Wegener's patients using overlapping peptides covering the full proteinase 3 sequence. Kidney Int 2000; 2001; 59.
- 48 Williams Rc Jr, Staud R, Malone CC, Payabyab J, Byres L & Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 1994; 152: 4722–37.
- 49 Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P & Barrett AJ. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450–7.
- 50 Molldrem J, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V & Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529–34.